References
1. Lam CG, Howard SC, Bouffet E, Pritchard-Jones K. Science and health
for all children with cancer. Science . 2019;363(6432):1182-1186.
doi:10.1126/science.aaw4892
2. Stanley CC, Westmoreland KD, Heimlich BJ, et al. Outcomes for
paediatric Burkitt lymphoma treated with anthracycline-based therapy in
Malawi. Br J Haematol . 2016;173(5):705-712. doi:10.1111/bjh.13986
3. Paintsil V, David H, Kambugu J, et al. The Collaborative Wilms Tumour
Africa Project; Baseline evaluation of Wilms tumour treatment and
outcome in eight institutes in sub-Saharan Africa. Eur J Cancer .
2015;51(1):84-91. doi:10.1016/j.ejca.2014.10.030
4. Magrath I, Steliarova-Foucher E, Epelman S, et al. Paediatric cancer
in low-income and middle-income countries. Lancet Oncol .
2013;14(3):e104-16. doi:10.1016/S1470-2045(13)70008-1
5. Howard SC, Zaidi A, Cao X, et al. The My Child Matters programme:
effect of public-private partnerships on paediatric cancer care in
low-income and middle-income countries. Lancet Oncol .
2018;19(5):e252-e266. doi:10.1016/S1470-2045(18)30123-2
6. Stanley CC, van der Gronde T, Westmoreland KD, et al. Risk factors
and reasons for treatment abandonment among children with lymphoma in
Malawi. Support Care Cancer . 2018;26(3):967-973.
doi:10.1007/s00520-017-3917-z
7. Khalek ER, Afungchwi GM, Beltagy M El, et al. Highlights from the
13th African Continental Meeting of the International Society of
Paediatric Oncology (SIOP), 6-9 March 2019, Cairo, Egypt.Ecancermedicalscience . 2019;13:932. doi:10.3332/ecancer.2019.932
8. Gopal S, Loehrer PJ. Global Oncology. JAMA - J Am Med Assoc .
2019;322(5):397-398. doi:10.1001/jama.2019.7081
9. WHO | Global Initiative for Childhood Cancer. WHO .
2018.
10. Dudgeon D. The Impact of Measuring Patient-Reported Outcome Measures
on Quality of and Access to Palliative Care. J Palliat Med .
2018;21(S1):S76-S80. doi:10.1089/jpm.2017.0447
11. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD.
Reporting of patient-reported outcomes in randomized trials: The CONSORT
PRO extension. JAMA - J Am Med Assoc . 2013;309(8):814-822.
doi:10.1001/jama.2013.879
12. Banerjee AK, Okun S, Edwards IR, et al. Patient-reported outcome
measures in safety event reporting: PROSPER consortium guidance.Drug Saf . 2013;36(12):1129-1149. doi:10.1007/s40264-013-0113-z
13. Mercieca-Bebber R, King MT, Calvert MJ, Stockler MR, Friedlander M.
The importance of patient-reported outcomes in clinical trials and
strategies for future optimization. Patient Relat Outcome Meas .
2018;9:353-367. doi:10.2147/PROM.S156279
14. Basch E. Patient-Reported Outcomes — Harnessing Patients’ Voices
to Improve Clinical Care. N Engl J Med . 2017;376(2):105-108.
doi:10.1056/NEJMp1611252
15. Basch E, Reeve BB, Mitchell SA, et al. Development of the National
Cancer Institute’s patient-reported outcomes version of the common
terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer
Inst . 2014;106(9). doi:10.1093/jnci/dju244
16. Basch E. The Missing Voice of Patients in Drug-Safety Reporting.N Engl J Med . 2010;362(10):865-869. doi:10.1056/NEJMp0911494
17. Hinds PS, Nuss SL, Ruccione KS, et al. PROMIS pediatric measures in
pediatric oncology: Valid and clinically feasible indicators of
patient-reported outcomes. Pediatr Blood Cancer .
2013;60(3):402-408. doi:10.1002/pbc.24233
18. Reeve BB, Edwards LJ, Jaeger BC, et al. Assessing responsiveness
over time of the PROMIS® pediatric symptom and function measures in
cancer, nephrotic syndrome, and sickle cell disease. Qual Life
Res . 2018;27(1):249-257. doi:10.1007/s11136-017-1697-z
19. Reeve BB, McFatrich M, Mack JW, et al. Expanding construct validity
of established and new PROMIS Pediatric measures for children and
adolescents receiving cancer treatment. Pediatr Blood Cancer .
2020;67(4):e28160. doi:10.1002/pbc.28160
20. Westmoreland K, Reeve BB, Amuquandoh A, et al. Translation,
psychometric validation, and baseline results of the Patient-Reported
Outcomes Measurement Information System (PROMIS) pediatric measures to
assess health-related quality of life of patients with pediatric
lymphoma in Malawi. Pediatr Blood Cancer . 2018;65(11):e27353.
doi:10.1002/pbc.27353
21. Montgomery ND, Liomba NG, Kampani C, et al. Accurate Real-Time
Diagnosis of Lymphoproliferative Disorders in Malawi Through
Clinicopathologic Teleconferences. Am J Clin Pathol .
2016;146(4):423-430. doi:10.1093/ajcp/aqw118
22. Westmoreland KD, El-Mallawany NK, Kazembe P, Stanley CC, Gopal S.
Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in
Malawi after anthracycline-based treatment. Br J Haematol .
2018;181(6):853-854. doi:10.1111/bjh.14716
23. Westmoreland KD, Stanley CC, Montgomery ND, et al. Hodgkin lymphoma,
HIV, and Epstein–Barr virus in Malawi: Longitudinal results from the
Kamuzu Central Hospital Lymphoma study. Pediatr Blood Cancer .
2017;64(5). doi:10.1002/pbc.26302
24. Lansky SB, List MA, Lansky LL, Ritter-Sterr C, Miller DR. The
measurement of performance in childhood cancer patients. Cancer .
1987;60(7):1651-1656.
doi:10.1002/1097-0142(19871001)60:7<1651::aid-cncr2820600738>3.0.co;2-j
25. Irwin DE, Gross HE, Stucky BD, et al. Development of six PROMIS
pediatrics proxy-report item banks. Health Qual Life Outcomes .
2012;10. doi:10.1186/1477-7525-10-22
26. Varni JW, Thissen D, Stucky BD, et al. PROMIS® parent proxy report
scales: An item response theory analysis of the parent proxy report item
banks. Qual Life Res . 2012;21(7):1223-1240.
doi:10.1007/s11136-011-0025-2
27. Varni JW, Thissen D, Stucky BD, et al. PROMIS ® Parent Proxy Report
Scales for children ages 5–7 years: an item response theory analysis of
differential item functioning across age groups. Qual Life Res .
23:349-361. doi:10.2307/24726304
28. Varni JW, Burwinkle TM. The PedsQLTM as a
patient-reported outcome in children and adolescents with
Attention-Deficit/Hyperactivity Disorder: A population-based study.Health Qual Life Outcomes . 2006;4:26. doi:10.1186/1477-7525-4-26
29. Bjorner JB, Rose M, Gandek B, Stone AA, Junghaenel DU, Ware JE.
Method of administration of PROMIS scales did not significantly impact
score level, reliability, or validity. J Clin Epidemiol .
2014;67(1):108-113. doi:10.1016/j.jclinepi.2013.07.016
30. Magnus BE, Liu Y, He J, et al. Mode effects between computer
self-administration and telephone interviewer-administration of the
PROMIS® pediatric measures, self- and proxy report. Qual Life
Res . 2016;25(7):1655-1665. doi:10.1007/s11136-015-1221-2
31. PROMIS Pediatric and Parent Proxy Profile Scoring Manual .;
2020. doi:10.32388/pvl6lk
32. Irwin DE, Stucky BD, Thissen D, et al. Sampling plan and patient
characteristics of the PROMIS pediatrics large-scale survey. Qual
Life Res . 2010;19(4):585-594. doi:10.1007/s11136-010-9618-4
33. PROMIS Score Cut Points.
https://www.healthmeasures.net/score-and-interpret/interpret-scores/promis/promis-score-cut-points.
Accessed July 4, 2020.
34. Thissen D, Liu Y, Magnus B, et al. Estimating minimally important
difference (MID) in PROMIS pediatric measures using the scale-judgment
method. Qual Life Res . 2016;25(1):13-23.
doi:10.1007/s11136-015-1058-8
35. Mack JW, McFatrich M, Withycombe JS, et al. Agreement Between Child
Self-report and Caregiver-Proxy Report for Symptoms and Functioning of
Children Undergoing Cancer Treatment. JAMA Pediatr . August
2020:e202861-e202861. doi:10.1001/jamapediatrics.2020.2861
36. Westmoreland KD, Montgomery ND, Stanley CC, et al. Plasma
Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis,
prognosis and response assessment in Malawi. Int J cancer .
2017;140(11):2509-2516. doi:10.1002/ijc.30682
37. Hinds PS, Wang J, Cheng YI, et al. PROMIS pediatric measures
validated in a longitudinal study design in pediatric oncology.Pediatr Blood Cancer . 2019;66(5). doi:10.1002/pbc.27606
38. Knaul FM, Farmer PE, Krakauer EL, et al. Alleviating the access
abyss in palliative care and pain relief—an imperative of
universal health coverage: the
<em>Lancet</em> Commission
report. Lancet . 2018;391(10128):1391-1454.
doi:10.1016/S0140-6736(17)32513-8
39. Liben S, Papadatou D, Wolfe J. Paediatric palliative care:
challenges and emerging ideas. Lancet . 2008;371(9615):852-864.
doi:10.1016/S0140-6736(07)61203-3
40. Weaver MS, Yao AJJ, Renner LA, Harif M, Lam CG. The prioritisation
of paediatrics and palliative care in cancer control plans in Africa.Br J Cancer . 2015;112(12):1845-1856. doi:10.1038/bjc.2015.158
41. DeWalt DA, Gross HE, Gipson DS, et al. PROMIS® pediatric self-report
scales distinguish subgroups of children within and across six common
pediatric chronic health conditions. Qual Life Res .
2015;24(9):2195-2208. doi:10.1007/s11136-015-0953-3
42. DeWalt DA, Thissen D, Stucky BD, et al. PROMIS pediatric peer
relationships scale: Development of a peer relationships item bank as
part of social health measurement. Heal Psychol .
2013;32(10):1093-1103. doi:10.1037/a0032670
43. Stanley CC, Westmoreland KD, Itimu S, et al. Quantifying bias in
survival estimates resulting from loss to follow-up among children with
lymphoma in Malawi. Pediatr Blood Cancer .
2017;64(6):10.1002/pbc.26370. doi:10.1002/pbc.26370
44. Gopal S, Gross TG. How I treat Burkitt lymphoma in children,
adolescents, and young adults in sub-Saharan Africa. Blood .
2018;132(3):254-263. doi:10.1182/blood-2018-04-844472
45. McGoldrick SM, Mutyaba I, Adams S V., et al. Survival of children
with endemic Burkitt lymphoma in a prospective clinical care project in
Uganda. Pediatr Blood Cancer . 2019;66(9). doi:10.1002/pbc.27813
46. Yao AJ-J, Moreira C, Traoré F, et al. Treatment of Wilms Tumor in
Sub-Saharan Africa: Results of the Second French African Pediatric
Oncology Group Study. J Glob Oncol . 2019;5(5):1-8.
doi:10.1200/jgo.18.00204
47. Patte C, Auperin A, Gerrard M, et al. Results of the randomized
international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin
lymphoma in children and adolescents: it is possible to reduce treatment
for the early responding patients. Blood . 2007;109(7):2773-2780.
doi:10.1182/blood-2006-07-036673
48. Wildes TM, Farrington L, Yeung C, et al. Rituximab is associated
with improved survival in Burkitt lymphoma: a retrospective analysis
from two US academic medical centers. Ther Adv Hematol .
2014;5(1):3-12. doi:10.1177/2040620713514682
49. Broderick JE, May M, Schwartz JE, et al. Patient reported outcomes
can improve performance status assessment: a pilot study. J
Patient-Reported Outcomes . 2019;3(1):41. doi:10.1186/s41687-019-0136-z
50. Myers RM, Balsamo L, Lu X, et al. A prospective study of anxiety,
depression, and behavioral changes in the first year after a diagnosis
of childhood acute lymphoblastic leukemia: a report from the Children’s
Oncology Group. Cancer . 2014;120(9):1417-1425.
doi:10.1002/cncr.28578
51. Njuguna F, Mostert S, Slot A, et al. Abandonment of childhood cancer
treatment in Western Kenya. Arch Dis Child Educ Pract Ed .
2014;99(7):609-614. doi:10.1136/archdischild-2013-305052
52. Togo B, Traoré F, Togo AP, et al. Épidémiologie et pronostic des
cancers pédiatriques au CHU Gabriel-Touré de Bamako (Mali). Med
Sante Trop . 2014;24(1):68-72. doi:10.1684/mst.2014.0291